Scientists have created a nanobody-based method that enables ultra-fast, high-resolution 3D mapping of neurons and glia in thick brain tissues. The researchers from Japan have developed a fast, high-sensitivity three dimensional immunohistochemistry (3D-IHC) method using nanobodies fused with peroxidase and a novel signal amplification system. … Read More
DDW’s Megan Thomas looks at a day in the life of Professor Kristian Reich, Co-Founder and CSO of MoonLake. MT: Can you tell us what you do and what you’re working on at the moment? KR: As Co-Founder and Chief Scientific Officer of MoonLake, an advancing biotechnology company without the… Read More
Grifols and biotechnology startup, FcR Therapeutics, have agreed to collaborate on recombinant nanobodies to treat autoimmune diseases. The nanobodies, which are small highly specialised antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of immune cells that… Read More
Scientists have developed a unique antibody platform to tackle the challenges of treating rapidly evolving viruses like SARS-CoV-2 due to their ability to mutate and evade therapies. Their findings introduce the Adaptive Multi-Epitope Targeting and Avidity-Enhanced (AMETA) Nanobody Platform. Dr Yi Shi, Associate Professor… Read More
Researchers from the Institute of Cardiovascular Sciences at the University of Birmingham, UK, have produced the first binding molecules (ligands) of defined composition to make platelets clump together in a predictable way. The research team, led by Professor Steve Watson and Dr Eleyna Martin, developed antibody… Read More
Amid the growing threat of a new and potentially more dangerous SARS-CoV-2 variant, scientists are ramping up the quest for Covid treatments. A recent study demonstrates the therapeutic potential of an unusual class of immune proteins: miniature antibodies called nanobodies, derived from llamas. Rockefeller University scientists Michael P. Rout and Brian T. Chait and… Read More
ChromoTek, part of Proteintech specialising in nanobody-based reagents, and Absolute Antibody, provider of recombinant antibody technology, have announced a partnership to offer recombinant engineered antibodies to scientists worldwide. The chimeric antibodies were originally derived from alpaca nanobodies and engineered onto mouse and rabbit Fc domains to open up new research… Read More
